Meeting Coverage > > ASH Video Pearls: Multiple Myeloma– Longer spaces in between anti-BCMA representatives related to better reaction rates, research study discovers
by Greg Laub, Director, Video, MedPage Today December 20, 2024
A retrospective analysis provided at the American Society of Hematology yearly conference took a look at several myeloma clients’ actions to teclistamab (Tecvayli), consisting of amongst those formerly treated with other B-cell maturation antigen (BCMA)-directed treatments.
In this special MedPage Today video, Jack Khouri, MD, of the Cleveland Clinic Taussig Cancer Institute, shares insights on sequencing BCMA-targeted treatments, consisting of a useful pointer to possibly improve client results with teclistamab.
Following is a records of his remarks:
We’ve been extremely fortunate in myeloma to have numerous actually efficient representatives targeting BCMA on the plasma cells. And we’re still attempting to determine how to series those treatments for our clients to enhance the actions.
We looked at clients who got teclistamab, which is a bispecific targeting BCMA, and these are clients that really had actually gotten, before teclistamab, other BCMA-directed treatments. And after that they were treated with teclistamab. A few of these BCMA-directed treatments consist of CAR T-cell treatment, other bispecific antibodies, and antibody-drug conjugates.
And after that we took a look at how these clients reacted to teclistamab. What we discovered was a lower total action rate with teclistamab if they had actually gotten prior BCMA-directed treatment. That’s a 51% total reaction rate versus a ~ 61% reaction rate for BCMA-naive clients. That’s a lower action rate. And after that there was a pattern towards an inferior progression-free survival compared to clients who are BCMA-naive. All in all, lower actions and possibly lower PFS, progression-free survival.
And after that we type of took a look at the space of time or the time off of BCMA treatment for clients who really reacted much better. Clients who had a time space of at least 9 months in between whatever BCMA-directed treatment they had and teclistamab, those are the clients that in fact had the finest actions.
I believe this is an actually valuable, kind of useful suggestion. If docs or professionals are thinking of utilizing or sequencing various BCMA-directive treatments, I believe permitting that time space in between those treatments really might improve actions for the clients.
-
Greg Laub is the Senior Director of Video and presently leads the video and podcast production groups. Follow
